![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Company announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™ o Exela Sterile Medicines LLC.
Lead Product(s): Neostigmine Methylsulfate
Therapeutic Area: Musculoskeletal Product Name: Bloxiverz
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Avadel Pharmaceuticals
Deal Size: $42.0 million Upfront Cash: $14.5 million
Deal Type: Divestment July 01, 2020